R&D of Innovative Medicines
The group has 9 innovative drugs under development in 2023, of which 5 are focused on respiratory diseases. These drugs include the dual-target new drug DBM-1152A (Shuobai) used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as several other new drugs that have entered phase I clinical trials. In addition, Health Element has also entered into strategic cooperation with multiple companies, such as the analgesic new drug FZ008-145 in cooperation with Fermion, the TSLP monoclonal antibody QX008N in cooperation with Quanxin Bio, the anti-IL-4Ra long-acting monoclonal antibody BA2101 injection in cooperation with Boan Bio, and the small molecule inhibitor in cooperation with Bayer. These collaborations further enrich the product line of Health Element Pharmaceutical and promote its rapid development in the field of innovative drugs.
In terms of innovative drug research and development, we have a mature platform for the development of biological innovative drug monoclonal antibodies and recombinant proteins. Among them, (i) recombinant human chorionic gonadotropin for injection has been approved for production; (ii) the recombinant novel coronavirus fusion protein vaccine (Likang V-01) has been approved for emergency use in China's sequential immunization and is being vaccinated nationwide. (iii) tocilizumab injection (recombinant humanized anti-human IL-6R monoclonal antibody injection) has been approved for marketing.
Quick Navigation
Service Hotline
Quick
Navigation
Service
Hotline
Official WeChat Official Account
Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved. Powered by:www.300.cn Zhuhai 粤ICP备14024104号